14-104773921-G-C

Variant summary

Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PM2

The NM_001382430.1(AKT1):​c.693C>G​(p.Asn231Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000686 in 1,458,622 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N231S) has been classified as Uncertain significance.

Frequency

Genomes: not found (cov: 33)
Exomes 𝑓: 6.9e-7 ( 0 hom. )

Consequence

AKT1
NM_001382430.1 missense

Scores

3
7
8

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: -0.369

Publications

0 publications found
Variant links:
Genes affected
AKT1 (HGNC:391): (AKT serine/threonine kinase 1) This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]
AKT1 Gene-Disease associations (from GenCC):
  • Proteus syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae)
  • Cowden disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Cowden syndrome 6
    Inheritance: Unknown Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 2 ACMG points.

PM2
Very rare variant in population databases, with high coverage;

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_001382430.1. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
AKT1
NM_001382430.1
MANE Select
c.693C>Gp.Asn231Lys
missense
Exon 9 of 15NP_001369359.1
AKT1
NM_001014431.2
c.693C>Gp.Asn231Lys
missense
Exon 8 of 14NP_001014431.1
AKT1
NM_001014432.2
c.693C>Gp.Asn231Lys
missense
Exon 9 of 15NP_001014432.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
AKT1
ENST00000649815.2
MANE Select
c.693C>Gp.Asn231Lys
missense
Exon 9 of 15ENSP00000497822.1
AKT1
ENST00000349310.7
TSL:1
c.693C>Gp.Asn231Lys
missense
Exon 9 of 15ENSP00000270202.4
AKT1
ENST00000402615.6
TSL:1
c.693C>Gp.Asn231Lys
missense
Exon 8 of 14ENSP00000385326.2

Frequencies

GnomAD3 genomes
Cov.:
33
GnomAD4 exome
AF:
6.86e-7
AC:
1
AN:
1458622
Hom.:
0
Cov.:
32
AF XY:
0.00000138
AC XY:
1
AN XY:
725376
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
33402
American (AMR)
AF:
0.00
AC:
0
AN:
44500
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26052
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39614
South Asian (SAS)
AF:
0.00
AC:
0
AN:
85712
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
53102
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5540
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1110488
Other (OTH)
AF:
0.00
AC:
0
AN:
60212
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.425
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome
Cov.:
33

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

Inborn genetic diseases Uncertain:1
Aug 31, 2023
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.N231K variant (also known as c.693C>G), located in coding exon 7 of the AKT1 gene, results from a C to G substitution at nucleotide position 693. The asparagine at codon 231 is replaced by lysine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.97
BayesDel_addAF
Benign
-0.17
T
BayesDel_noAF
Benign
-0.49
CADD
Benign
17
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.55
D
Eigen
Benign
-0.72
Eigen_PC
Benign
-0.92
FATHMM_MKL
Benign
0.40
N
LIST_S2
Uncertain
0.94
D
M_CAP
Benign
0.041
D
MetaRNN
Uncertain
0.52
D
MetaSVM
Benign
-0.96
T
MutationAssessor
Benign
0.61
N
PhyloP100
-0.37
PrimateAI
Pathogenic
0.85
D
PROVEAN
Pathogenic
-5.4
D
REVEL
Uncertain
0.31
Sift
Uncertain
0.0010
D
Sift4G
Uncertain
0.019
D
Polyphen
1.0
D
Vest4
0.95
MutPred
0.63
Gain of catalytic residue at E228 (P = 0.0065)
MVP
0.64
MPC
2.2
ClinPred
0.99
D
GERP RS
-7.1
PromoterAI
-0.086
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.99
gMVP
0.86
Mutation Taster
=17/83
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.19
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs767346459; hg19: chr14-105240258; API